sale growth led china quarter
maintain buy rate maintain tp
deriv tp base estim ep
forward look price-to-earnings give upsid
potenti estim
revenu growth
estim base follow factor strong growth
revenu earn strong growth china approv
keytruda fda treatment
world-wide sale merck increas
exclud neg impact foreign exchang
sale grew driven growth oncolog vaccin
ep quarter non- ep
increas quarter
sale repres total sale quarter
perform led china sale growth
driven vaccin oncolog
merck announc five addit approv keytruda
global includ nsclc china rcc kn-
 keytruda growth y/i includ
market
lynparza sale doubl quarter driven ovarian
mainten launch expand ovarian
indic europ
compani namemerck compani inctickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric jul week week volum volum day errorp/ ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth merck compani inc juli
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vaccin sale growth driven gardasil
gardasil fuel on-going commerci launch china
demand europ partial off-set public sector
buy pattern pediatr vaccin includ
proquad mmr-ii varivax rotateq also
contribut vaccin growth
bridion revenu grew growth
reflect increas util bridion procedur
neuromuscular blockad revers agent use
on-going prevymi launch contribut perform
growth companion anim led bravecto drove
sale quarter growth also support new
poultri swine product sale custom buy
pattern within busi livestock well
neg impact fx off-set demand growth
merck close acquisit antelliq group
establish merck leader digit anim
identif traceabl monitor solut
merck narrow rais revenu rang
includ neg impact
foreign exchang slightli mid-
april exchang rate merck narrow rais
gaap ep rang non-
gaap ep rang
stock price histori date high name date name move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date jun last split factor new per last split date feb inform merck compani inc juli
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger acquisition- total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli balanc sheet
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item
provid oper activ compar
increas cash oper activ reflect high oper effici
provid invest activ compar cash use invest activ
chang due higher proce sale secur
use financ activ compar cash provid financ
activ chang due higher purchas treasuri stock repurchas capit
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end merck compani inc juli
merck strongest quarter recent histori due strong growth
keytruda gardasil bridion intern market sale china
increas total revenu increas y/i ep
increas previou year
total revenu increas compar
increas revenu due higher sale
oncolog franchis reflect strong growth keytruda monotherapi
chemo combo first line lung cancer
hospit care franchis due bridion inject
papillomaviru hpv vaccin gardasil strong presenc
anim health contribut sale growth quarter due bravecto
despit higher total sale growth off-set due declin
immunolog franchis semponi remicad saw
declin respect virolog zepati saw declin
cardiovascular franchis zetia vytorin saw declin
respect intern sale low europ canada
compar
gross margin
compar
cog decreas
decreas due amort intang asset relat
acquisit busi capit mileston payment also off-set
expens relat restructur activ
gross margin compar
increas due favor effect foreign exchang
product mix increas amort intang asset off-set
unfavor affect gross margin ppt compar
ppt
improv gross margin result lower acquisit
non-gaap gross margin compar
non-gaap gross margin increas quarter compar
due favor effect foreign exchang partial gross
margin also affect amort intang asset
unfavor effect price royalti
sg expens decreas compar
decreas expens reflect lower promot sell
cost despit off-set higher administr cost
 expens reduc compar
decreas due charg format eisai
record partial off-set increas expens clinic
drug develop
non-gaap expens increas compar
previou year quarter increas reflect higher cost
clinic develop drug develop collabor
incom expens net expens compar
incom non-gaap incom expens net
expens compar incom non-
incom expens net reflect gain legal settlement
effect incom tax rate reflect benefit
relat settlement certain prior incom tax matter
net incom increas compar
ep increas compar
non-gaap ep compar
compar
gaap ep increas
compar
compar
merck two busi segment pharmaceut anim health
segment consist human health vaccin
product health product use treatment human
disord therapeut prevent agent drug sold
pharmaceut segment revenu increas
compar increas due oncolog
vaccin partial off-set lower sale hospit acut care
cardiovascular immunolog
total revenu pharmaceut segment increas
compar total intern
revenu increas compar
oncolog segment shown massiv growth key factor
growth keytruda higher usag monotherapi chemo
combo first line lung cancer adjuv treatment patient
melanoma first line treatment patient stage non small cell
keytruda revenu increas compar
high growth volum multipl market led high
revenu quarter merck continu launch keytruda multipl
keytruda revenu increas
compar first line lung cancer key reason
growth unit state back first approv adjuv
melanoma renal cell carcinoma
increas
compar
increas
compar
total intern revenu keytruda increas
compar china main contributor
intern growth sinc launch metastat melanoma last year
strong sale keytruda first line lung cancer also
got approv china promis long term growth potenti japan
acceler growth due recent approv adjuv melanoma
high cancer util chemo combo first line lung cancer
recent approv europ combin chemotherapi first line
treatment metastat squamou nsclc also led increas revenu
lynparza revenu increas
increas revenu due doubl sale driven
approv us market
perform vaccin busi shown growth due higher
sale gardasil/gardasil m-m-r
gardasil revenu increas compar
gardasil vaccin use prevent certain
cancer diseas caus human papillomaviru hpv
increas revenu due higher sale intern market
especi china europ wherea partial off-set domest
gardasil revenu decreas
compar decreas gardasil/gardasil
sale unit state reflect public sector buy pattern
gardasil intern revenu increas
compar higher demand vaccin
rate boy girl europ on-going commerci launch china
led higher growth intern sale
keytruda revenu
 increas
compar
increas
compar
proquad/m-m-r ii /varivax revenu increas
compar pediatr vaccin varivax
use prevent chicken pox prevent measl
mump growth intern market remain robust
increas higher demand europ growth
domest market
vaccin perform neg affect pneumovax
vaccin prevent pneumonia revenu increas
compar domest sale
increas
intern market decreas
factor growth hospit acut care bridion inject
use revers neuromuscular blockad adult undergo surgeri
bridion revenu increas compar
increas sale mainli due growth
domest market increas util procedur
revenu
compar
increas
compar
bridion revenu increas
compar total intern revenu increas
compar
simponi remicad two element immunolog sold
intern market total revenu simponi decreas
compar high
volum sale europ off-set foreign exchang rate
total revenu remicad decreas
compar unfavor effect foreign
exchang affect sale perform alongwith market exclus
europ also affect high competit
total revenu isentress isentress hd declin
compar sale declin us
sale declin
intern market declin
declin due highli competit pressur us
total revenu zepati declin
compar intern sale declin
total revenu
simponi declin
compar
total global sale
zetia declin
compar
total global sale zetia declin
decreas sale primarili due lower sale
major part europ high level competit market forc
sale come domest intern market
total revenu januvia janumet decreas
compar decreas revenu due
high level price pressur unit state global demand remain
singulair revenu increas compar
nasonex revenu declin compar
total revenu nuvar increas
compar increas off-set unfavor
effect foreign exchang us patent expir last year also
contribut declin sale
anim health segment includ vaccin pharmaceut product
prevent treat diseas farm companion anim speci
total revenu anim health product decreas
compar decreas revenu due
unfavor factor foreign exchang higher demand
bravacto use parasit control
increas volum growth livestock product especi new
poultri swine product off-set unfavor effect foreign
total revenu
januvia janumet
decreas
compar
total revenu
nuvar increas
compar
total revenu livestock decreas
compar total revenu
compar total intern revenu
compar
total revenu
livestock decreas
compar
total revenu companion anim
total revenu compar
total intern revenu compar
anti therapi keytruda got approv unit state
intern market differ type tumor
approv base clinic trial broad clinic
develop program trial combin keytruda
cancer treatment studi includ type cancer
keytruda combin tyrosin kinas inhibitor inlyta axitinib
review europ first line treatment advanc renal cell
carcinoma fda approv keytruda april indic
phase keynote- trial show improv os
fda accept prioriti review supplement bla keytruda
monotherapi advanc small-cel lung cancer sclc patient
progress line therapi supplement bla base
phase phase trial keytruda
combin chemotherapi studi phase keynote-
patient newli diagnos extens stage sclc
fda accept supplement bla keytruda also combin
platinum chemotherapi first line treatment
patient recurr metastat hnscc base phase
keytruda show improv os compar
standard monotherapi patient diagnos tumor
combin posit score greater equal greater
equal fda grant prioriti review correspond applic
also pend europ
fda design keytruda breakthrough therapi treatment
earli stage high risk tripl neg breast cancer combin
prioriti review
supplement bla
keytruda
monotherapi
keytruda
treatment earli
committe medicin product use european
medicin agenc posit opinion lynparza oral parp
inhibitor first line mainten treatment patient brca
posit result base phase trial statist signific
clinic meaning improv lynparza reduc risk
diseas progress death
posit result phase polo trial doubl blind placebo-
control trial explor efficaci lynparza tablet first line
mainten monotherapi patient germlin brca mutat
 brca metastat adenocarcinoma pancrea
progress platinum-bas chemotherapi
ema accept market author applic
investig vaccin ebola zair diseas applic biolog
licens process fda
condit approv keytruda grant china nation medic
product administr first line treatment metastat nonsquam
nsclc combin chemotherapy-bas trial anti-
keytruda first get approv one tumor type
separ pivot phase trial patient metastat castration-
resist prostat cancer mcrpc evalu keytruda
combin chemotherapi lynparza anti-hormon agent
prioriti review new drug investig beta-lactamas inhibitor
relebactam combin imipenem/cilastatin treatment
infect caus gram-neg bacteria adult
committe medicin
product use
european medicin
agenc posit
opinion lynparza
condit approv
tabl show pipelin product develop differ phase
phase phase phase entri date review cancer keytruda advanc solid tumor prostat lenvima biliari tract cavatak melanoma colorect lynparza advanc solid tumor cancer keytruda breast octob cervic octob eu colorect novemb cutan squamou cell april esophag decemb gastric may eu hepatocellular may eu mesothelioma may nasopharyng april ovarian decemb small cell lung may eu lenvima endometri june melanoma march non-small-cel lung march lynparza pancreat decemb prostat april new molecular entities/vaccin bacteri infect relebactam imipenem/cilastatin eu ebola vaccin eu cancer supplement file cancer keytruda first line advanc renal cell carcinoma eu first line metastat non-smal cell lung cancer eu third line advanc small cell lung cancer first line head neck cancer eu lynparza first-lin advanc ovarian cancer eu habp/vabp zerbaxa cytomegaloviru cough gefapix march diabet mellitu heart failur vericiguat septemb infect pneumoconjug vaccin june pediatr neurofibromatosi type selumetinib respiratori syncyti viru schizophrenia footnot develop collabor develop collabor keytruda develop current hold registr studi roll submiss habp hospit acquir bacteri pneumonia/vabp ventilator-associ bacteri pneumonia merck compani inc juli
merck expect revenu
includ neg impact foreign exchang
ep expect non-
gaap ep expect
effect tax rate expect non-
tax rate
merck start year strong perform quarter
due growth keytruda gardasil bridion total revenu increas
ep increas
non-gaap ep compar revenu
quarter off-set immunolog cardiovascular segment
anti therapi keytruda got approv unit state
intern market type tumor combin inlyta
review europ first line treatment advanc renal cell carcinoma
merck acquir antelliq corpor leader digit technolog
livestock anim health
keytruda revenu increas compar
lynparza revenu compar
european union approv keytruda combin chemotherapi
first line treatment adult metastat squamou non small cell lung
total revenu anim health product increas
compar ytd stock perform
roe roa
revenu
impact foreign
merck start year
strong
perform
quarter due growth
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin decreas increas cog compar
ttm basi
revenu growth ttm basi compar
oper margin increas compar ttm basi
increas oper margin due lower sg expens
ep increas ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc juli
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale merck compani inc juli
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item merck compani inc juli
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free merck compani inc juli
current price-to-earnings trade due increas stock price
well ep averag price-to-earnings price-to-earnings trade averag price-to-earnings avg-
expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit world wellington manag compani jp morgan america geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard washington mutual investor incom fund america spdr etf vanguard institut fund-institut vanguard specialized-health fidel american balanc ishar merck compani inc juli
developmentsfda approv recarbrio treatment adult complic unrinari tract complic intra-abdomin bacteri infect limit altern treatment option avail juli food drug administr approv recarbrio new combin antibacteri gram inject indic patient age older limit altern treatment option treatment complic urinari tract infect includi pyelonephr recarbrio use case prevent infect reduc develop drug resist bacteria maintain effect recarbrio fda accept merck supplement biolog licens applic keytruda six week dose schedul melanoma multipl indic juli food drug administr accept review six supplement biolog licens applic updat dose frequenc keytruda merck seek fda approv dose infus minut indic melanoma classic hodkin lymphoma primari mediastin larg b-cell lymphoma gastric cancer hepatocellular carcinoma merkel cell carcinoma merck complet tender offer acquir immun designapril known msd outsid unit state canada announc success complet cash tender offer subsidiari outstand share common stock immun design purchas price per share tender offer expir share common stock immun design validli tender withdrawn tender offer repres outstand common stock immun design fulli dilut basi share accept payment accord term tender offer merck expect promptli pay share merck complet acquisit antelliq corpor becom leader emerg digit technolog livestock companion animalsapril known msd outsid unit state canada announc complet acquisit antelliq corpor fund advis bc partner today announc posit compani global leader anim health digit track traceabl monitor technolog complement exist portfolio vaccin pharmaceut antelliq oper unit within merck anim health merck compani inc juli
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
price-to-earnings ratio ttm
industri averag
gross margin ttm
industri averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc juli
consensu view analyst trend stock
forecast
higher
compar
forward price-to-earnings
higher
mrk avgfive-year growth forecast usdgrowth high day day day estim comparisonmrkindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate merck compani inc juli
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
merck stock price show upward trend quarter
merck gave return quarter current trade
stock price upward trend year increas price dip march
april recov current trade
stock price increas may due strong perform oper benefit
stock show upward trend result reach time high
stock given return past year
merck perform driven oncolog vaccin busi well strong growth
china maintain buy rate stock tp base forward price-to-earnings
multipl non-gaap estim ep expect revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
